CoreValve gets CE mark
This article was originally published in The Gray Sheet
Executive Summary
Firm will not immediately launch its ReValving percutaneous aortic valve following European clearance announced May 16 for high-risk patients. Instead, an expanded clinical evaluation at selected centers will focus on physician training, appropriate patient selection and gathering clinical feedback, the firm says. It expects data from a mandatory patient registry to help support FDA go-ahead to start a clinical trial for the device in the United States. Competitor Edwards Lifesciences, which received FDA approval for a U.S. trial in March, expects CE mark later this year for its Sapien transcatheter aortic valve. The firm recently filed a patent suit against CoreValve in Germany (1"The Gray Sheet" May 14, 2007, In Brief)...
You may also be interested in...
Edwards v. CoreValve
Edwards Lifesciences files transcatheter heart valve patent suit against competitor CoreValve in the District Court of Dusseldorf, Germany May 10. Edwards, developer of the Sapien transcatheter aortic valve, says it has an exclusive sublicense to the patent in question from Johnson & Johnson/Heartport. Edwards, which anticipates European commercialization of Sapien by year-end, is discussing a possible licensing arrangement with CoreValve, which had hoped to launch its ReValving transcatheter aortic valve in Europe in early 2007. Edwards recently received FDA go-ahead to begin a trial to support approval of its device in the United States (1"The Gray Sheet" March 26, 2007, p. 10)...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.